IMMX vs IMNN

Immix Biopharma, Inc. vs Imunon, Inc. — Valuation Comparison 2026

IMMX

Pharmaceutical Preparations
Immix Biopharma, Inc.
Quality
5.1
out of 10
Value Trap
30
LOW
Price
$9.00
Last close
Models
8/13
Active
VS

IMNN

Pharmaceutical Preparations
Imunon, Inc.
Quality
4.4
out of 10
Value Trap
38
LOW
Price
$2.18
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType IMMX Fair ValueIMMX Upside IMNN Fair ValueIMNN Upside
Bayesian DCF Intrinsic $3.14 -65.2% $1.10 -49.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.10 -96.3%
Dynamic NAV Asset-Based $1.61 -82.1% $8.98 +312.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMMX vs IMNN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMMX vs IMNN — Which Stock Is More Undervalued?

IMMX scores higher with a 5.1/10 quality rating vs IMNN's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Immix Biopharma, Inc. (IMMX) and Imunon, Inc. (IMNN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMMX currently trades at $9.00 with a QOC of 5.1/10, while IMNN trades at $2.18 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).